As of 2025-12-15, the Intrinsic Value of Cardiol Therapeutics Inc (CRDL.TO) is -1.75 CAD. This CRDL.TO valuation is based on the model Peter Lynch Fair Value. With the current market price of 1.47 CAD, the upside of Cardiol Therapeutics Inc is -218.92%.
Based on its market price of 1.47 CAD and our intrinsic valuation, Cardiol Therapeutics Inc (CRDL.TO) is overvalued by 218.92%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -1.75 - -1.75 | -1.75 | -218.92% |
| P/E | (2.96) - (4.20) | (3.71) | -352.1% |
| DDM - Stable | (2.95) - (11.36) | (7.16) | -586.7% |
| DDM - Multi | (0.53) - (1.60) | (0.80) | -154.1% |
| Market Cap (mil) | 146.25 |
| Beta | 1.89 |
| Outstanding shares (mil) | 99.49 |
| Enterprise Value (mil) | 134.76 |
| Market risk premium | 5.10% |
| Cost of Equity | 9.54% |
| Cost of Debt | 5.00% |
| WACC | 9.53% |